Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Asad S, Hulgan T, Raffanti SP, Daugherty J, Ray W, Sterling TR.

J Natl Med Assoc. 2008 Dec;100(12):1417-24.


Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States.

Beer L, Mattson CL, Bradley H, Skarbinski J; Medical Monitoring Project..

Medicine (Baltimore). 2016 Mar;95(13):e3171. doi: 10.1097/MD.0000000000003171.


Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T.

HIV Clin Trials. 2009 May-Jun;10(3):181-92. doi: 10.1310/hct1003-181.


Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006.

Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Skinner J, Frei CR.

South Med J. 2011 Dec;104(12):794-800. doi: 10.1097/SMJ.0b013e318236c23a.


Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.


A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team.; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)..

Lancet. 2006 Dec 16;368(9553):2125-35.


Clinical implications of antiretroviral drug interactions with warfarin: a case-control study.

Esterly JS, Darin KM, Gerzenshtein L, Othman F, Postelnick MJ, Scarsi KK.

J Antimicrob Chemother. 2013 Jun;68(6):1360-3. doi: 10.1093/jac/dkt043.


Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.

Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M.

HIV Clin Trials. 2007 Jan-Feb;8(1):1-8.


Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R; ACTG-ALLRT Protocol Team..

Oncology. 2011;80(1-2):42-9. doi: 10.1159/000328032.


Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.

Scherrer AU, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS)..

PLoS One. 2012;7(11):e50307. doi: 10.1371/journal.pone.0050307. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/78eea40b-1982-4734-b32e-f94ec6d7b85a.


Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).

Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):441-8. doi: 10.1097/QAI.0b013e3181609da8.


Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Aragão F, Vera J, Vaz Pinto I.

PLoS One. 2012;7(9):e44774. doi: 10.1371/journal.pone.0044774.


Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS.

Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E.

J Gen Intern Med. 2001 Dec;16(12):850-9.


Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review.


Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.


Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.


Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.


Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.

Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team..

AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.


Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.

Rahim S, Fredrick LM, da Silva BA, Bernstein B, King MS.

HIV Clin Trials. 2009 Mar-Apr;10(2):94-103. doi: 10.1310/hct1002-94.

Items per page

Supplemental Content

Support Center